Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.

[1]  M. Bains,et al.  Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Y. Doki,et al.  Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  V. Rusch,et al.  Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Judy L. Smith,et al.  Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Ginsberg,et al.  INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Marinus,et al.  MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA* , 2002, The Journal of Biological Chemistry.

[7]  M. Meyers,et al.  Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. , 2001, Cancer research.

[8]  M. Talamini,et al.  Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Wang,et al.  Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells , 1999, British Journal of Cancer.

[10]  T. Kunkel,et al.  The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. , 1998, Cancer research.

[11]  P. Soulié,et al.  Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. , 1997, European journal of cancer.

[12]  J. Bosset,et al.  Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. , 1997, The New England journal of medicine.

[13]  S. Aebi,et al.  The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.

[14]  T. Walsh,et al.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.

[15]  J. Cooper,et al.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.

[16]  D. Cain,et al.  National cancer institute sponsored cooperative clinical trials , 1990, Cancer.

[17]  Y. Robert,et al.  [Correlation of diameters measured by x-ray computed tomography and intraparietal extension of squamous cell carcinoma of the thoracic esophagus. Apropos of 101 anatomoradiologic comparisons]. , 1990, Journal de chirurgie.

[18]  C. S. Yang,et al.  Research on esophageal cancer in China: a review. , 1980, Cancer research.